Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1

NCT01420068 is registered in ClinicalTrials.gov with Noden Pharma as lead sponsor.

NCT NCT01420068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01420068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Double-blind 52 to 104 Week Off-therapy Extension Study to Evaluate the Long Term Growth and Development of Pediatric Hypertensive Patients 6 - 17 Years of Age Previously Treated With Aliskiren in Studies CSPP100A2365 and/or CSPP100A2365E1
Lead sponsor
Noden Pharma
Phase
Observational
Overall status
Completed
Start date
August 19, 2011
Completion date
August 3, 2017
Enrollment
106 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension